Teen Reasoning Skills Linked to Lower Dementia Risk, Study Suggests
A large population study indicates that better thinking ability in youth is associated with reduced dementia risk decades later, though the relationship is not fully understood.
A new report highlights evidence from large population studies suggesting that people who perform better on thinking ability tests during their teenage years or early adulthood are less likely to develop dementia later in life. The association appears robust across multiple cohorts, but the source stops short of claiming a direct cause-and-effect relationship.
The report notes a key caveat: the link between sharper reasoning skills in youth and reduced dementia risk is not yet fully explained. Researchers are still working to understand whether early cognitive ability directly protects the brain or whether it reflects other factors, such as education, lifestyle, or genetics, that influence both thinking skills and long-term brain health.
While the findings add to a growing body of evidence that cognitive function in early life may offer clues about dementia risk decades later, the source emphasizes that more research is needed. For now, the study serves as a reminder that the roots of late-life brain health may extend far back into youth.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.